Skip to main content
Premium Trial:

Request an Annual Quote

SeraCare Inks Deal to Offer AccuRef Reference Materials

NEW YORK (GenomeWeb) — SeraCare Life Sciences announced today that it has signed an agreement under which it will offer AccuRef Diagnostics' line of CRISPR-engineered cell line reference materials.

Under the terms of the deal, Milford, Massachusetts-based SeraCare will market and sell AccuRef's portfolio of CRISPR-engineered cell line-based cancer reference materials beginning in January in all markets except for China. The deal includes products geared for low-to-mid plex clinical genomic applications such as qPCR, digital PCR, Sanger sequencing, mass spec, and small targeted next-generation sequencing gene panels.

Additional terms were not disclosed.

AccuRef — a Milpitas, California-based division of global molecular and cellular reference standards provider Applied StemCell — was established last year.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.